Edgewood Management LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 35,401 shares of the company’s stock after buying an additional 43 shares during the period. Edgewood Management LLC’s holdings in Johnson & Johnson were worth $4,079,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of JNJ. Stokes & Hubbell Capital Management LLC increased its position in Johnson & Johnson by 0.3% in the third quarter. Stokes & Hubbell Capital Management LLC now owns 89,666 shares of the company’s stock valued at $10,592,000 after buying an additional 269 shares during the period. Oliver Luxxe Assets LLC increased its position in Johnson & Johnson by 3.6% in the third quarter. Oliver Luxxe Assets LLC now owns 14,651 shares of the company’s stock valued at $1,731,000 after buying an additional 512 shares during the period. Pure Financial Advisors Inc. increased its position in Johnson & Johnson by 16.1% in the third quarter. Pure Financial Advisors Inc. now owns 3,399 shares of the company’s stock valued at $401,000 after buying an additional 472 shares during the period. Bremer Trust National Association increased its position in Johnson & Johnson by 1.9% in the third quarter. Bremer Trust National Association now owns 22,727 shares of the company’s stock valued at $2,685,000 after buying an additional 432 shares during the period. Finally, Independence Advisors LLC increased its position in Johnson & Johnson by 52.5% in the third quarter. Independence Advisors LLC now owns 6,244 shares of the company’s stock valued at $738,000 after buying an additional 2,150 shares during the period. 65.30% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson (NYSE:JNJ) traded down 0.09% during trading on Friday, hitting $121.76. 7,089,257 shares of the stock traded hands. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $129.00. The company’s 50 day moving average price is $125.22 and its 200 day moving average price is $118.10. The company has a market cap of $330.38 billion, a P/E ratio of 20.53 and a beta of 0.74. Johnson & Johnson also saw unusually large options trading on Tuesday. Investors bought 3,039 put options on the stock. This represents an increase of 415% compared to the average daily volume of 590 put options.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 18th. The company reported $1.83 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.77 by $0.06. The company earned $17.77 billion during the quarter, compared to analyst estimates of $18.02 billion. Johnson & Johnson had a return on equity of 25.61% and a net margin of 22.78%. The firm’s revenue was up 1.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.68 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post $7.04 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was originally published by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/edgewood-management-llc-boosts-stake-in-johnson-johnson-jnj-updated-updated/525584.html.
Several research firms have recently commented on JNJ. BTIG Research reissued a “hold” rating on shares of Johnson & Johnson in a report on Wednesday. Barclays PLC restated an “equal weight” rating and issued a $130.00 price target (up previously from $125.00) on shares of Johnson & Johnson in a research report on Monday. Jefferies Group LLC restated a “hold” rating and issued a $132.00 price target (up previously from $125.00) on shares of Johnson & Johnson in a research report on Saturday, March 11th. Vetr cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $119.73 price target on the stock. in a research report on Tuesday, March 7th. Finally, Wells Fargo & Co cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and boosted their price target for the stock from $112.28 to $112.80 in a research report on Thursday, January 26th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $125.53.
In other Johnson & Johnson news, VP Paulus Stoffels sold 22,000 shares of the company’s stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $117.29, for a total transaction of $2,580,380.00. Following the completion of the sale, the vice president now directly owns 127,650 shares in the company, valued at $14,972,068.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.11% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with our FREE daily email newsletter.